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nanomedjournal.comAbstract
Interaction between the complement system and carbon nanotubes (CNTs) can modify their intended biomedical applications. Pristine and
derivatised CNTs can activate complement primarily via the classical pathway which enhances uptake of CNTs and suppresses pro-inflammatory
response by immune cells. Here, we report that the interaction of C1q, the classical pathway recognition molecule, with CNTs involves charge
pattern and classical pathway activation that is partly inhibited by factor H, a complement regulator. C1q and its globular modules, but not factor H,
enhanced uptake of CNTs by macrophages andmodulated the pro-inflammatory immune response. Thus, soluble complement factors can interact
differentially with CNTs and alter the immune response evenwithout complement activation. Coating CNTswith recombinant C1q globular heads
offers a novel way of controlling classical pathway activation in nanotherapeutics. Surprisingly, the globular heads also enhance clearance by
phagocytes and down-regulate inflammation, suggesting unexpected complexity in receptor interaction.
From the Clinical Editor: Carbon nanotubes (CNTs) maybe useful in the clinical setting as targeting drug carriers. However, it is also well
known that they can interact and activate the complement system, which may have a negative impact on the applicability of CNTs. In this study,
the authors functionalized multi-walled CNT (MWNT), and investigated the interaction with the complement pathway. These studies are
important so as to gain further understanding of the underlying mechanism in preparation for future use of CNTs in the clinical setting.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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carbon nanotubes (CNTs) from the systemic circulation by the
immune system can seriously undermine the intended applica-
tion of nanoparticles as intravenous drug delivery platforms.1
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strategic and specific in vivo use.1–6
The innate immune system plays a key role in the recognition
and clearance of pathogens, altered-self, and synthetic particles
including nanoparticles.1,3,6–8 The complement system is one of
the key innate immune mechanisms and is activated through
three pathways. The classical pathway is initiated by C1q, a
charge pattern recognition protein consisting of 18 chains (6A,
6B and 6C) each composed of an N-terminal collagen domain
(cC1q) and a C-terminal globular head (gC1q) domain. These
polypeptides assemble to form a structure of 6 heterotrimeric
globular heads, linked together by the collagen regions. C1q
most notably binds to IgG and IgM-bearing immune complexesis an open access article under the CC BY-NC-ND license
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hydrophobic patches on self, non-self and altered-self targets.9,10
C1q binding to its targets activates proteases C1r and C1s, which
are bound to the cC1q domain, and C1s activates C4 and C2
forming C4b2a (a C3 convertase) which activates C3, forming
C3a and C3b, of which the latter can bind to the target surface.
C3b and its breakdown products iC3b and C3d interact with
C3 receptors on phagocytic cells.10 C3b also binds to C4b2a,
forming C4b2a3b, a protease that can bind and activate C5,
and ultimately drives formation of C5b-9 (the membrane attack
complex; MAC), which forms a channel in membranes, lysing
cells.10 In the lectin pathway, binding of MBL or ficolins to
targets via vicinal-diols or acetyl-groups on sugars activates
MASPs, leading to C4 and C2 activation.10 In the alternative
pathway, hydrolysis of a thiol-ester in C3 to form C3(H2O)
results in formation of a complex with factor B, which is cleaved
by factor D, to form C3(H2O)Bb (a homologue of C4b2a).
C3(H2O)Bb activates C3, to form C3a and C3b, which can
bind covalently to surfaces. Surface-bound C3b then interacts
with factor B and factor D to yield C3 convertase (C3bBb).
C3bBb, an unstable protease, can be stabilized by properdin to
form C3bBbP. Factor H (FH) regulates the alternative pathway
by binding to C3b, inhibiting interaction with factor B, and
then factor I, a regulatory protease, cleaves C3b in the C3b-FH
complex to form iC3b, a potent opsonin, which is unable to
form C3bBb.10–12 Like C1q, FH binds to targets mainly via
interactions with charge clusters, and thus competes with C1q
for binding to some targets, thereby also inhibiting classical
pathway activation.11,13
Pristine and functionalized CNTs activate complement, mainly
through the classical pathway, and to a minor extent through the
alternative3,4,6,8,14–18 and the lectin pathways.4,19,20 Complement
activation by CNTs offers an intriguing challenge since C3b-
opsonized CNTs can be cleared via complement receptors on
phagocytes21 prior to reaching the targeted tissue for drug delivery.
Complement by-products (C3a, C4a, and C5a) are potent
anaphylatoxins, and can induce inflammation and hypersensitivity
reactions.3,8,10 MAC formation can potentially cause damage to
cells and tissues in close vicinity of complement-activating
nanoparticles.6 Classical pathway-activating CNTs get internalized
more efficiently by macrophages, leading to down-regulation of
pro-inflammatory cytokines.21 However, Au–Ni nanowires of
similar dimensions activate complement very poorly, causing
reduced phagocytosis and increased pro-inflammatory response by
immune cells.22 Complement deposition can potentially sequester
CNTs away from PAMP-PRR engagement on immune cell surfaces,
and dampen inflammation via up-regulation of anti-inflammatory
IL-10.22
Surface modifications of hydrophobic CNTs are essential to
disperse them in aqueous media that can be achieved by covalent
or non-covalent surface coating. Non-covalent adsorption of
dispersants (proteins, polymers and nucleic acids) onto the CNT
surface does not alter their structure. Covalent functionalization
alters their walls by making small defects, commonly via
oxidation, leading to carboxyl groups on the surface.23 Here, we
functionalized a type of pristine multi-walled CNT (MWNT),
covalently by oxidation (Ox-MWNT), or non-covalently with
carboxymethyl-cellulose (CMC-MWNT), each having carboxylfunctional groups. Given that CNTs (pristine or functionalized)
offer repetitive recognition patterns of polarity and hydropho-
bicity, we examined the nature of interaction of C1q, the
first recognition subcomponent of the classical pathway,
with Ox-MWNT and CMC-MWNT. We also included FH in
the study, a competitive inhibitor of C1q for certain ligands,
which can act as a regulator of classical as well as alternative
pathway.24 Both C1q and FH, which can be locally synthesised
during immune cell activation, can have functions without
involving complement activation.25 Here, we show differential
interaction of C1q and FH with CNTs, which can impact upon
complement activation, phagocytosis, and immune response.Methods and materials
Dispersion of MWNTs by non-covalent and covalent
functionalization
MWNTs were purchased from Arry Nano, Germany with an
outer diameter of 10-20 nm and a length of 5-20 μm. Non-covalent
functionalization was achieved by 2 min sonication in PBS in 2:1
mass ratiowithCMC (Sigma), followed by centrifugation at 8000g to
remove clusters, washing in PBS, and filtration of excess CMC using
a 0.2 μmfilter (Whatman). For covalent functionalization, amodified
procedure described by Li et al23 was used. 100 mg of pristine
MWNTswas added to a 50 mlmixture of H2SO4 (10 M) andHNO3
(10 M) in 3:1 ratio, sonicated in a water-bath (RT for 1 h), and then
probe-sonicated for 30 min (50% ON, 50% OFF) on ice, in order to
exfoliate the MWNTs and homogenize the dispersion. After being
refluxed at 120 °C for 48 h, the resulting mixture of Ox-MWNTs,
after being cooled down and diluted with distilled water, was
centrifuged at 11,000g for 30 min. Water was added to the pellets to
re-suspend Ox-MWNTs and then centrifuged three times. The
amorphous carbon due to the partial oxidation of the outer structure
was removed by stirring the Ox-MWNTs in 10 mM NaOH
overnight.26 The dispersion was then filtered through a 0.1 μm
filter, followed by extensive washing in water in order to remove
NaOH. Ox-MWNTs were dialyzed against distilled water and
washed in PBS.
Purification of C1q and factor H from human plasma
C1q and FH were purified from human plasma as described
previously.13
Recombinant human C1q globular head modules (ghA, ghB and
ghC) and substitution mutants
The ghA, ghB and ghC modules and their substitution mutants
(ArgA162Ala/Glu, ArgB114Gln/Glu, HisB117Asp, ArgB129Ala/Glu,
LysB136Glu, ArgB163Ala/Glu, TyrB175Leu, HisC101Ala, ArgC156Glu,
LysC170Glu) were expressed as fusion proteins linked to maltose
binding protein (MBP) in Escherichia coli BL21 and purified using
amylose resin.27–29 These mutants were selected based on earlier data
showing their involvement in C1q binding to a range of ligands
including IgG, IgM, CRP and PTX3. LPS was removed using
Polymyxin B agarose gel (Sigma) and its level was determined by
Limulus amebocyte lysate assay (BioWhittaker, USA) (∼4 pg μg−1
for ghA and ghB; ∼5 pg μg−1 for ghC).
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C1q, ghA, ghB, ghC, substitution mutants and FH were
incubated overnight (2:1 weight ratio) with CMC-MWNT or
Ox-MWNT in affinity buffer (50 mM Tris–HCl, pH 7.5,
150 mM NaCl, 5 mM CaCl2) and unbound proteins were
washed away by repeated centrifugation at 17,000g for
10 min. Protein binding was analyzed by SDS-PAGE under
reduced conditions. A range of protein:CNT weight ratios was
analyzed (1:2, 1:1, 2:1, 4:1 and 8:1) and 2:1 ratio was found to be
optimal.
Complement consumption and hemolytic assays for the
classical pathway
A complement consumption assay was performed as
described earlier6 to examine modulation of the classical
pathway activation by protein-coated CNTs. Samples of coated
and uncoated CMC-MWNT and Ox-MWNT (100 μg/ml in
affinity buffer) were incubated with occasional shaking at 37 °C
for 1 h with an equal volume of human serum 1:1 diluted in
dextrose gelatin veronal buffer (DGVB++; 2.5 mM sodium
barbital, 71 mM NaCl, 0.15 mM CaCl2, 0.5 mM MgCl2, 2.5%
w/v glucose, 0.1% w/v gelatin, pH7.4). This was followed by
centrifugation (13,000g, 10 min), and the collected supernatants
were tested for their complement activity by measuring the
capacity to lyse antibody-sensitized sheep erythrocytes (EA;
Ref. 6). 100 μl of EA cells (1 × 108 cells/ml in DGVB++) were
added to serial dilutions (100 μl) of each supernatant in
DGVB++ and incubated for 1 h at 37 °C. Following centrifuga-
tion (5000 rpm, 5 min), 100 μl of the supernatant was collected
and released hemoglobin was measured at 405 nm. Total
hemolysis (100%) was measured by lysing EA with water.
Background spontaneous hemolysis (0%) was determined by
incubating EA with buffer (DGVB++) only. Serum diluted
identically but without CNTs was used as positive control.
Biotinylation of CNTs
CMC-MWNT and Ox-MWNT were dialyzed into 0.1 M
MES buffer, pH 5 and their concentration adjusted to 0.2 mg/ml.
Pentylamine biotin (Pierce; 2 mg) was added to 2 ml of
CMC-MWNT or Ox-MWNT and 20 μl of a 20 mg/ml solution
of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochlo-
ride (EDC, Sigma) was added and incubated at RT for 2 h with
stirring, and then biotinylation was stopped by adding 100 μl of
0.1 M ethanolamine pH 8.2 (Sigma). The resulting biotin-
CMC-MWNT and biotin-Ox-MWNT were dialyzed against PBS
in order to remove residual reactants and MES.
Phagocytosis assay
U937 cells (a monocytic cell line derived from histiocytic
lymphoma) were cultured in complete RPMI-1640 (GIBCO)
containing 10% fetal calf serum (FCS), 2 mM L-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin and 1 mM sodium
pyruvate (all from Sigma), and passaged and washed in AIM-V
Albumax serum free medium (GIBCO) before use. In each
well of a 24 well plate, 5 × 105 cells were seeded in AIM-V
AlbuMAX serum free medium with supplements but no FCS.Twenty micrograms of biotin-CMC-CNT or biotin-Ox-MWNTs
coated with C1q, factor H, ghA, ghB or ghC was added to each
well and incubated for 6 h. Cells were harvested and washed
5 times in PBS (centrifugation at 300g) and stored at −80 °C
until further use. All experiments were performed in duplicate.
For quantification of phagocytosis,21 25 μl lysis buffer
(10 mM HEPES, 20 mM NaCl, 0.5 mM EDTA, 1% w/v Triton
X 100) was added to the cell pellets. After cell lysis, 25 μl of
0.1 mg/ml horse IgG (MRC ICU, Oxford) in PBS was added (as
a blocking agent) to the dispersion. Microtitre wells (NUNC,
polysorb) were coated with 100 μl Avidin (Pierce) at 50 μg/ml
in 0.1 M Na2CO3, pH 9.0 for 1 h at RT, followed by blocking
with 1 mg/ml horse IgG in PBS for 1 h at RT. Next, 50 μl of a
solution or cell lysate containing biotin-CMC-MWNT or
biotin-Ox-MWNT and 50 μl of 0.1 mg/ml horse IgG was
incubated for 1 h in each well. The plate was washed 7 times
with 0.1 mg/ml horse IgG in PBS to remove excess CNTs and
then incubated with 1:2000 Streptavidin–HRP (Sigma) for 1 h at
RT. TMB (Biolegend, UK) was used as a substrate for HRP and
the yellow product was read at 450 nm.
Isolation of human macrophages and fluorescence microscopy
CMC-MWNTs were suspended in 0.1 M MES, pH 5 and
labeled with AlexaFluor488-cadaverine (Invitrogen) for 2 h at
RT in a 2:1 mass ratio in the presence of 1 mM EDC. Labeled
CMC-MWCNTs were recovered by centrifugation (10,000g,
10 min) and washed 3 times with PBS to remove unincorporated
label. Purified proteins were incubated overnight at a 2:1 mass
ratio with AlexaFluor488-cadaverine labeled CMC-MWNT in
affinity buffer at 4 °C with agitation. Excess protein was
removed by washing twice with PBS. Treated AlexaFluor488-
cadaverine labeled CMC-MWNTs were recovered by centrifu-
gation and dispersed in PBS in a water bath sonicator.
The uptake of protein-treated and untreated, fluorescently-labeled
CMC-MWNT was examined using monocyte-derived human
macrophages as described in Ref. 22. Human PBMCs (1 × 106)
were seeded on 13 mm diameter cover slips and incubated for
14 days at 37 °C, 5% CO2 in a humidified atmosphere. Mature
macrophages were exposed to 4 μg/ml protein-treated or untreated
AlexaFluor488-cadaverine labeled CMC-MWCNTs in 500 μl of
serum-free medium for 3 h. Cells were washed twice with PBS,
fixed with 4% formaldehyde for 10 min, washed twice, and
processed for immunofluorescence. The coverslips were stained
for 30 min with 1.6 μM Hoechst 33342 and 2 μg/ml Alexa-
Fluor546-conjugatedwheat germ agglutinin (Invitrogen). Cellswere
thenwashed twice,mounted usingCitifluor anti-fade (Citifluor, UK)
and observed with a Zeiss 780 confocal microscope with 40×
oil-lens using ZEN software (Zeiss, UK).
Quantitative PCR analysis for cytokine mRNA expression
In a 24-well plate, 10 μg of protein-coated CMC-MWNTs or
Ox-MWNTs in 500 μl of PBS were added to each well
containing 5 × 105 U937 cells in AIM-V Albumax serum-free
medium and incubated for 15, 30, 45, 60, 120 or 360 min inside
a 5% CO2–95% air incubator at 37 °C (PBS only for 30 min as
control). Cells were harvested and spun down (3000g, 5 min)
and stored at −80 °C. Total RNA was extracted from frozen cell
Figure 1. (a) High resolution TEM image of pristine MWNT showing a high number of undamaged parallel carbon walls. The external diameter is ~22 nm while
the inner diameter of the CNT is only 5 nm; scale bar is 5 nm. (b) The outer walls of Ox-MWNT, after acid treatment at high temperature, show a high number of
defects, indicative of carboxyl group functionalization on the outer surface; scale bar is 10 nm. (c) During the oxidation process, although Ox-MWNTs are
shortened, the overall structure remains intact. (d) Cartoon depicting the oxidation process.
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Kit (Sigma-Aldrich). Following DNase treatment, samples were
heated at 70 °C for 10 min to inactivate DNase and RNase, and
then chilled on ice. The amount of total RNA was determined at
260 nm using the NanoDrop 2000/2000c spectrophotometer
(Thermo-Fisher Scientific), and the purity using the ratio of
absorbance at 260/280 nm ratio. The cDNA was synthesized
using High Capacity RNA to cDNA Kit (Applied Biosystems)
using 2 μg of total RNA extract.
Primer sequences, designed and analyzed for specificity via http://
blast.ncbi.nlm.nih.gov/Blast.cgi), included: 18S forward
(5′-ATGGCCGTTCTTAGTTGGTG-3′) , 18S reverse
(5′-CGCTGAGCCAGTCAGTGTAG-3′); IL-1β forward (5′-GGA
CAAGCTGAGGAAGATGC-3′), IL-1β reverse (5′-TCGTTATCC
CATGTGTCGAA-3′); IL-6 forward (5′-GAAAGCAGCAAA
GAGGCACT-3′), IL-6 reverse (5′-TTTCACCAGGC
AAGTCTCCT-3′); IL-10 forward (5′-TTACCTGGAGGAGGTG
ATGC-3′), IL-10 reverse (5′-GGCCTTGCTCTTGTTTTCAC-3′);
IL-12 forward (5′-AACTTGCAGCTGAAGCCATT-3′), IL-12
reverse (5′-GACCTGAACGCAGAATGTCA-3′); TGF-β for-
ward (5′-GTACCTGAACCCGTGTTGCT-3′), TGF-β reverse (5′-G
TATCGCCAGGAATTGTTGC-3′); TNF-α forward (5′-AGCCC
ATGTTGTAGCAAACC-3′), TNF-α reverse (5′-TGAGGTACA
GGCCCTCTGAT-3′); NF-κB forward (5′-GTATTTCAACCACA
GATGGCACT-3′), NF-κB reverse (5′-AACCTTTGCTGGTCCCA
CAT-3′); NLRP3 forward (5′-GCCATTCCCTGACCAGACTC-3′)
and NLRP3 reverse (5′-GCAGGTAAAGGTGCGTGAGA-3′).
The qPCR reaction (10 μl) consisted of 5 μl Power SYBR
Green MasterMix (ABI), 75 nM of forward and reverse primerand 500 ng template cDNA. PCR was performed using a Step
One Plus Real-Time PCR System (ABI). After initiation steps of
2 min at 50 °C and 10 min at 95 °C, the template was amplified
for 40 cycles (15 s at 95 °C, 1 min at 60 °C). Samples were
normalized using the expression of human 18S rRNA. Data were
analyzed using the Step One software v2.3. Ct (cycle threshold)
values for each cytokine target gene were calculated. Relative
expression of each cytokine target gene was calculated using
the Relative Quantification (RQ) value, using the equation:
RQ = 2−ΔΔCt for each cytokine target gene, and comparing
relative expression with that of the 18S rRNA constitutive gene
product. Assays were conducted in triplicate.
Multiplex cytokine array analysis
Cytokines (IL-6, IL-8, IL-10, IL12p40, IL12p70, IL-23,
IL-27, IL-1α and IL-1β) and chemokines/growth factors (MIG,
I-TAC, MCP-1, G-CSF and M-CSF) concentrations in the
supernatants of U937 cells were measured by MagPix Milliplex
kit (EMD Millipore). Cells were incubated with protein-coated
and uncoated CMC-MWNTs and Ox-MWNTs as above for
48 h, and then spun down at 300g and supernatants were stored
at −80 °C until use. Briefly, 25 μl of assay buffer was added to
each well of a 96-well plate, followed by addition of 25 μl of
standard, controls or supernatants of (CNT treated) cells, to
appropriate wells. Twenty-five microliters of magnetic beads
coupled to analytes was added in each well, and incubated for
18 h at 4 °C. After washing the plate with assay buffer, 25 μl of
detection antibodies was incubated with the beads for 1 h at RT.
Figure 3. Complement consumption assay. CNTs were coated with the
proteins (1:4 ratio) overnight and washed, followed by incubation with
human serum for 1 h. Serum incubated without CNTs acted as a negative
control. % complement consumption was calculated as (C − Ci)/C × 100%,
where C is total complement activity in CH50 units of the negative control,
Ci the amount of activity remaining in the supernatant. All experiments were
done in triplicate; error bars represent ± standard deviation.
Figure 2. (A) SDS-PAGE of purified proteins bound to Ox-MWNTs. CNTs
were coated with the proteins (1:2 ratio) for 2 h. Lane 1: standard marker;
Lanes 2, 3 and 4 containing: ghA, ghB and ghC, respectively (each
~60 kDa); Lane 5: equimolar ghA, ghB and ghC; Lane 6: factor H
(~155 kDa); Lane 7: C1q (A, B, and C chains at ~20-25 kDa); Lane 8:
marker. (B) SDS-PAGE of purified proteins bound to CMC-CNTs. CNTs
were coated with the proteins as above Lane 1: molecular weight marker;
Lane 2: ghA; Lane 3: ghB; Lane 4: ghC; Lane 5: equimolar ghA, ghB and
ghC; Lane 6: C1q; Lane 7: factor H. In Fig. 2, A and B, the additional band in
the C1q tracks (above 70 kDa) may arise from aggregation of C1q C chain, or
incomplete dissociation of C1q.
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added and incubated for 30′. Following a washing step, 150 μl of
sheath fluid (BD Biosciences) was added to each well and the
plate was read using the Luminex Magpix instrument.Results
Oxidation, coating and dispersion of CNTs
Pristine MWNTs of 5-20 μm length and a diameter of
10-20 nm (Figure 1, A) were well-dispersed by non-covalent
coating with CMC; being stable over months, no sedimentation/
clustering is seen (by light microscopy; not shown). Oxidation
was achieved by treatment with concentrated acids (Figure 1, D).
Defects seen on the surface of the Ox-MWNTs via TEM imaging
(Figure 1, B) were absent on pristine MWNTs (Figure 1, A); CNTs
were significantly shortened (length 100-500 nm; Figure 1, C).
NaOH treatment removed all amorphous carbon from the CNTsurface. Ox-MWNTs were stable over months even at N1 mg/ml
without clustering/sedimentation.
Binding of wild type and substitution mutants of individual C1q
globular domains to CNTs suggests a charge–charge interaction
C1q and FH both bound to CMC-MWNTs and Ox-MWNTs
(Figure 2, A, B; lanes 6, 7). Differential binding of ghA, ghB and
ghC and their mutants can be seen in Supplementary Figure 1.
For Ox-MWNT, binding of ghA and ghB was stronger than ghC
(Figure 2, A; lanes 2-5). For CMC-MWNT, binding of ghB was
stronger than ghA and ghC (Figure 2, B; lanes 2-5). ArgA162
appeared important since binding decreased for ArgA162Ala, while
wild-type andArgA162Glu bound similarly (Supplementary Figure
1, A and B). Substitution of Lys136 to Glu (LysB136Glu) abolished
binding completely. Furthermore, ArgB129 substitution had a
negative effect. When Arg129 was substituted for Ala, a decrease
in bindingwas observed, while substitution for Glu did not have an
effect. No other ghB substitutions (ArgB114Gln/Glu, HisB117Asp,
ArgB163Ala/Glu, TyrB175Leu) had a large influence on binding.
For ghC, mutants HisC101Ala and LysC170Glu did not have an
effect on binding; however, ArgC156Glu showed an increase in
binding. Thus, C1q binds to CNT surface patterns in a manner
different from its natural ligands, especially IgG and IgM.Residues
that have previously shown to be peripheral and subsidiary for
gC1q interaction with natural ligands seem important for
interaction with CNTs.
Coating of CNTs with innate immune humoral factors and effect
on classical pathway complement activation
When C1q-coated Ox-MWNT and CMC-MWNT were
examined for the classical pathway activation, complement
consumption was inhibited by 40% for Ox-MWNTs but there
Figure 4. Differential phagocytosis by macrophages of CMC-CNTs coated with C1q, factor H, ghA, ghB and ghC. (A) 0.5 × 106 U937 cells were incubated with
20 μg of protein-coated biotin-CNTs for 6 h. The cells were lysed and the amount of CNTs was quantified by an ELISA type assay. A standard curve with
known concentrations of biotin-CMC-CNTs was performed in the same assay to calculate the mass of the CNTs in the cell samples. All experiments were done
in triplicate; error bars represent ± standard deviation. (B) In vitro assessment of uptake of protein-treated and untreated fluorescently labeled CMC-MWNTs by
human blood macrophages. Cells were incubated for 3 h with Alexa 488 cadaverine labeled-CMC-MWNTs (green) pre-incubated with C1q, factor H, ghA, ghB
or ghC, or a mix (ghABC). Cells were fixed and stained with Alexa546-labeled WGA to reveal the plasma membrane (red). The nucleus was stained with
Hoechst 33342 (blue). Single confocal sections are shown, scale bars 20 μm. (C) Magnified orthogonal views of the same confocal images demonstrate uptake
of Alexa 488 cadaverine labeled-CMC-MWNTs (green, arrows) for all proteins but factor H (small arrow), scale bar 10 μm.
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differential orientation of C1q on the CNT surface. CNT-bound
C1q must either sequester C1r and C1s from C1 in the serum, or
be replaced by C1. Since ghA, ghB and ghC do not apparently
dissociate (see below), the interaction of C1q with Ox-MWNT
may be at least partially in a conformation which does not allow
capture of C1r and C1s. Coating with ghA, ghB and ghC also
considerably inhibits the classical pathway activation by
serum.21 CNTs, when pre-coated with FH (Figure 3), were
also able to consume 40% less complement than the uncoated
CNTs. This indicates that FH is inhibiting binding of C1 (C1q)from serum, possibly recognizing motifs that are overlapping/
identical to those recognized by C1q, consistent with the
emerging evidence that for certain C1q ligands, such as anionic
phospholipids, lipid A, apoptotic cells and β amyloid peptide
1-42, FH can be an inhibitor of the classical pathway.11,13,24,30Effect of CNT coating with C1q, ghA, ghB, ghC and factor H on
phagocytosis by U937 cell line and human macrophages
For CMC-MWNT, phagocytosis was increased byC1q (3.5-fold),
ghA (4-fold), and ghC (7-fold) (Figure 4, A). For Ox-MWNT, no
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phagocytosis was slightly higher with C1q (1.3 fold). For FH, a 2.6
fold reduction of uptake of Ox-MWNT was seen, but FH did not
enhance or diminish uptake of CMC-MWNT. The enhancement of
CMC-MWNT uptake by individual gC1q modules is novel and
curious. Confocal microscopy using human macrophages confirmed
that C1q and the recombinant gC1q modules, but not FH, enhanced
uptake of CMC-MWNTs (Figure 4,B). Single confocal sections with
highermagnificationof themembrane revealedqualitative localization
of CNTs inside the cells except in the case of FH (Figure 4, C).
Cytokine and transcription factor mRNA expression by U937
cells treated with protein-coated Ox-MWNTs and CMC-MWNTs
IL-10 mRNA expression by U937 cells was dramatically
up-regulated (300-fold by 6 h) by Ox-MWNT from 15 min
onwards (Supplementary Figure 2); for CMC-MWNT, the
up-regulationwas seen only after 2 h. For Ox-MWNT, pre-coating
with C1q and ghC dampened the IL-10 expression compared to
uncoated Ox-MWNTs. For CMC-MWNTs, all proteins except FH
had an inhibitory effect on IL-10, ghC being the most pronounced.
IL-12 transcription was considerably up-regulated for
Ox-MWNTs by ghA, ghB and ghC, but not as much as by C1q
and FH. IL-12 expression was down-regulated by CMC-MWNT
on its own, and further dampened by FH. For Ox-MWNTs, TGF-β
was down-regulated by C1q, but overall up-regulated by FH, ghB
and ghC, suggesting an immunosuppressive effect. However, for
CMC-MWNT, C1q and gC1q modules up-regulated TGF-β
transcripts while FH down-regulated, suggesting pattern-
dependent modulation of anti-inflammatory response. IL-1β was
up-regulated for all Ox-MWNT; for CMC-MWNT, there was
initially a down-regulation of IL-1β, but it increased at 2 h and 3 h,
consistent with NLRP3 expression. For IL-6, CMC-CNT
(uncoated) caused a consistently moderate down-regulation,
which was generally reversed by coating with C1q, FH, ghA,
ghB and ghC. TNF-α was up-regulated by Ox-MWNTs; most
proteins induced up-regulation at various time points, consistent
with NF-κB expression profile (Supplementary Figure 2).
Modulatory effects of protein-coated CNTs on
cytokine/chemokine secretion by U937 cells
Cytokine array analysis using supernatants at 48 h from
experiments as in Supplementary Figure 2 revealed that FH
suppressed MCP-1, IL-8 and TNF-α (FH more pronounced for
Ox-MWNT), IL-10, IL-1α and IL-1β. C1q, as opposed to FH,
enhanced TNF-β, IL-1β, IL-10 and G-CSF secretion. All three
globular modules suppressed IL-8 and G-CSF, while TNF-α was
suppressed by ghB and ghC. IL-10 secretionwas slightly enhanced
whereas ghB considerably suppressed IL-1α and IL-1β for
CMC-MWNT. They also enhanced G-CSF production whereas
only ghA was able to enhance IL-12 secretion (Figure 5).Discussion
Due to a range of structural and functional attributes, CNTs have
wide ranging applications in translational medicine.31–35 Their
systemic administration for vaccination and drug delivery31,34,36inevitably brings them in contact with complement. Any surface that
offers amolecular pattern as a signature of non-self and altered-self is
amenable to complement recognition and activation. Complement
deposition on CNTs, mainly via the classical pathway,3,6,17,21
enhances their uptake by complement receptor bearingAPCs such as
macrophages and B cells and down-regulates pro-inflammatory
cytokines21 via up-regulation of IL-10.22 Curiously, Au–Ni
nanowires,22,37 being poor complement activators, are potent
inducers of pro-inflammatory response following serum treatment,
suggesting that coating with other serum proteins in the absence of
complement deposition can have deleterious consequences.22 This
brought the focus of this study on the nature of the interaction
between C1q9 and CNTs.
All three recombinant globular head modules (ghA, ghB,
ghC) bind onto the surface indicating the binding of C1q onto
CNTs is likely through charge pattern recognition, which would
enable binding of C1r and C1s via C1q for further complement
activation. Coating the globular heads lead to effective inhibition
of complement activation.21 We used single residue substitute
mutations of ghA, ghB and ghC in order to identify gC1q
residues involved in the CNT-C1q interaction. These residues
were selected for substitution mutation because of being
hypervariable within the 3-D structure of the gC1q domain and
their central/subsidiary involvement in interaction with known
C1q ligands.27–29,38 We also examined the effects of CNT
coating by C1q, ghA, ghB, ghC, and FH (as a potential
down-regulator of the classical pathway) on phagocytosis and
cytokine expression by macrophages. Salvador-Morales et al8
have shown that FH reduces complement activation by CNTs
through the alternative pathway. For a number of C1q ligands, FH
acts an inhibitor of C1q, and thus dampens the classical
pathway.11,13,24,30 C1q and FH can be locally synthesized in
tissues, and thus bind to CNTs and alter their interaction with
immune cells without involving complement activation.
C1q is a versatile pattern recognition innate immune molecule
that recognizes an array of self, non-self and altered-self ligands.
The broad-spectrum ligand-binding potential of C1q, and its
subsequent effect on biological processes, is facilitated by the
modular organisation of the heterotrimeric gC1q domain (where
each module can have independence of structure and function),
its ability to change its conformation in a very subtle way, and
the manner in which this ancient molecule has evolved.9,38–40
The versatility and variability of C1q–ligand interaction are due
to differences in electrostatic surface potentials of the different
gC1q modules.41 Substitution mutants used here were designed
based on structure–function studies and ConSurf42 where the
most variable residues in the C1q family were considered most
likely to be central to C1q–ligand interaction. Thus, ArgB114 and
ArgB129, known to be important for C1q–IgG interaction27 did
not seem crucial for CNTs. Interestingly, an increase of binding
was found for substitution of the ArgC156 to Glu. These results
appear to suggest involvement of side chains and hydrophobic
patches within the gC1q domain in their interaction with CNTs.
Binding of macromolecules on CNTs is not fully explored, but
may involve charge transfer and hydrophobic interaction.43,44
Thus, molecular patterns offered by CNTs are likely to act as a
nucleation centre for an ordered binding of C1q and FH. Here,
residues within the gC1q domain that are peripheral/subsidiary to
Figure 5. Multiplex cytokine array analysis of supernatants of U937 cells treated with Ox-MWNT and CMC-CNT coated or uncoated with proteins for 24 h.
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involved in C1q-CNT interaction. These molecular patterns may
impact upon the level of C1q binding to CNTs, their clearance by
phagocytic cells, and cellular toxicity.
Oxidized CNTs are in general considered less toxic than
pristine CNTs.45–51 These effects, and few disagreements, are
due to reduction of impurities (catalyst) in the samples, a
decrease in length of CNTs, an increase of functional groups, and
higher dispersability leading to higher bioavailability.52,53
Bio-persistence is an important parameter for nanoparticle
in vivo toxicity. In contrast to pristine CNTs, highly carboxylated
CNTs were shown to be rapidly (within 3 h) cleared out of the
systematic circulation through the renal excretion route.48
Possible enzymatic degradation of CNTs with HRP49,54 and
myeloperoxidase (expressed in neutrophils)55 can thus be avoided
since CNT oxidation reduces the time required for degradation.49,56
Thus, coating and downstream processing of CNTs can generate
new molecular signatures that can be recognized by complement
proteins including C1q.
The dissection of C1q interaction with CNTs is insightful
given that C1q is capable of binding charge clusters, polar
regions, or small hydrophobic patches.38 Since CNTs offer
repetitive patterns of polarity and hydrophobicity, C1q is well
suited to bind them, activate the classical pathway, and also
enhance their phagocytic uptake directly, even without further
complement deposition. Here, we report that coating CNTs with
recombinant globular heads can inhibit the classical pathway
activation, enhance uptake of CNTs by phagocytic cells, and at
the same time down-regulate pro-inflammatory cytokine re-
sponse by macrophages: a very novel and surprising result since
these molecules lack the collagen region of human C1q, which is
generally thought to be implicated in binding to receptors
involved in phagocytosis. However, there is at least one putative
receptor, gC1qR which recognizes globular heads.25 Thus, the
mechanism of enhancement of CNT uptake by globular heads of
C1q needs to be examined in future studies. We report a novel
method of inhibition of nanoparticle-mediated activation of the
classical pathway and subsequent handling by phagocytic cells
through an anti-inflammatory route. In view of planned trials
using CNTs coated with therapeutic antibodies35,57–60 which are
likely to offer an array of closely spaced Fc regions for C1q to
bind, the study offers an opportunity to modify drug vehicles.Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.nano.2015.06.009.References
1. Hussain S, Vanoirbeek JAJ, Hoet PHM. Interactions of nanomaterials
with the immune system. Wiley Interdiscip Rev Nanomed Nanobiotech-
nol 2012;4:169-83.
2. Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, Dobrovolskaia MA.
Minireview: nanoparticles and the immune system. Endocrinology
2010;151:458-65.3. Rybak-Smith M, Pondman K, Flahaut E, Salvador-Morales C, Sim R.
Recognition of carbon nanotubes by the human innate immune system. In:
Klingeler R, Sim RB, editors. Carbon Nanotub. Biomed. Appl.Springer;
2011. p. 183-210.
4. Andersen AJ, Wibroe PP, Moghimi SM. Perspectives on carbon
nanotube-mediated adverse immune effects. Adv Drug Deliv Rev
2012;64:1700-5.
5. Dumortier H. When carbon nanotubes encounter the immune system:
desirable and undesirable effects. Adv Drug Deliv Rev 2013;65:2120-6.
6. Salvador-Morales C, Flahaut E, Sim E, Sloan J, Green ML, Sim RB.
Complement activation and protein adsorption by carbon nanotubes.
Mol Immunol 2006;43:193-201.
7. Salvador-Morales C, Townsend P, Flahaut E, Venien-Bryan C, Vlandas
A, GreenMLH, et al. Binding of pulmonary surfactant proteins to carbon
nanotubes; potential for damage to lung immune defense mechanisms.
Carbon 2007;45:607-17.
8. Salvador-Morales C, Basiuk EV, Basiuk VA, Green MLH, Sim RB.
Effects of covalent functionalization on the biocompatibility character-
istics of multi-walled carbon nanotubes. J Nanosci Nanotechnol
2008;8:2347-56.
9. Kishore U, Reid KB.Modular organization of proteins containingC1q-like
globular domain. Immunopharmacology 1999;42:15-21.
10. Carroll MV, Sim RB. Complement in health and disease. Adv Drug
Deliv Rev 2011;63:965-75.
11. Kishore U, Sim RB. Factor H as a regulator of the classical pathway
activation. Immunobiology 2012;217:162-8.
12. Kouser L, Abdul-Aziz M, Nayak A, Stover CM, Sim RB, Kishore U.
Properdin and factor H: opposing players on the alternative complement
pathway “see-saw”. Front Immunol 2013;4:93.
13. Tan LA, Yu B, Sim FCJ, Kishore U, Sim RB. Complement activation by
phospholipids: the interplay of factor H and C1q. Protein Cell
2010;1:1033-49.
14. Hamad I, Hunter AC, Rutt KJ, Liu Z, Dai H, Moghimi SM.
Complement activation by PEGylated single-walled carbon nanotubes
is independent of C1q and alternative pathway turnover. Mol Immunol
2008;45:3797-803.
15. Moghimi SM, Hunter AC. Complement monitoring of carbon
nanotubes. Nat Nanotechnol 2010;5:382 [author reply 382–3].
16. Ling WL, Biro A, Bally I, Tacnet P, Deniaud A, Doris E, et al. Proteins
of the innate immune system crystallize on carbon nanotubes but are not
activated. ACS Nano 2011;5:730-7.
17. Rybak-Smith MJ, Sim RB. Complement activation by carbon nanotubes.
Adv Drug Deliv Rev 2011;63:1031-41.
18. Rybak-Smith MJ, Tripisciano C, Borowiak-Palen E, Lamprecht C, Sim
RB. Effect of functionalization of carbon nanotubes with psychosine on
complement activation and protein adsorption. J Biomed Nanotechnol
2011;7:830-9.
19. Andersen AJ, Robinson JT, Dai HJ, Hunter AC, Andresen TL, Moghimi
SM. Single-walled carbon nanotube surface control of complement
recognition and activation. ACS Nano 2013;7:1108-19.
20. Andersen AJ, Windschiegl B, Ilbasmis-Tamer S, Degim IT, Hunter AC,
Andresen TL, et al. Complement activation by PEG-functionalized
multi-walled carbon nanotubes is independent of PEG molecular mass
and surface density. Nanomedicine 2013;9:469-73.
21. Pondman KM, Sobik M, Nayak A, Tsolaki AG, Jäkel A, Flahaut E, et al.
Complement activation by carbon nanotubes and its influence on the
phagocytosis and cytokine response by macrophages. Nanomedicine
2014;10:1287-99.
22. PondmanKM, Tsolaki AG, Paudal B, ShamjiMH, Switzer A, PathanAA, et
al. Complement deposition on nanoparticles canmodulate immune responses
by macrophage, B and T cells. J Biomed Nanotechnol 2015 [in press].
23. Li Y, Zhang X, Luo J, Huang W, Cheng J, Luo Z, et al. Purification of
CVD synthesized single-wall carbon nanotubes by different acid oxidation
treatments. Nanotechnology 2004;15:1645-9.
24. Tan LA, Yang AC, Kishore U, Sim RB. Interactions of complement
proteins C1q and factor H with lipid A and Escherichia coli: further
2118 K.M. Pondman et al / Nanomedicine: Nanotechnology, Biology, and Medicine 11 (2015) 2109–2118evidence that factor H regulates the classical complement pathway.
Protein Cell 2011;2:320-32.
25. Kouser L, Madhukaran SP, Shastri A, Saraon A, Ferluga J, Al-Mozaini M,
et al. Emerging and novel functions of complement protein C1q. Front
Immunol 2015;6:317.
26. Verdejo R, Lamoriniere S, Cottam B, Bismarck A, Shaffer M. Removal
of oxidation debris from multi-walled carbon nanotubes. Chem Commun
2007:513-5.
27. Kojouharova MS, Gadjeva MG, Tsacheva IG, Zlatarova A, Roumenina LT,
Tchorbadjieva MI, et al. Mutational analyses of the recombinant globular
regions of human C1q A, B, and C chains suggest an essential role for
arginine and histidine residues in the C1q–IgG interaction. J Immunol
2004;172:4351-8.
28. Roumenina LT, RusevaMM, Zlatarova A, Ghai R, KolevM, Olova N, et al.
Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational
studies using recombinant globular head modules of human C1q A, B, and C
chains. Biochemistry 2006;45:4093-104.
29. Gadjeva MG, Rouseva MM, Zlatarova AS, Reid KBM, Kishore U,
Kojouharova MS. Interaction of human C1q with IgG and IgM:
revisited. Biochemistry 2008;47:13093-102.
30. Kang Y-H, Urban BC, Sim RB, Kishore U. Human complement Factor
H modulates C1q-mediated phagocytosis of apoptotic cells. Immuno-
biology 2012;217:455-64.
31. Bianco A, Kostarelos K, Prato M. Applications of carbon nanotubes in
drug delivery. Curr Opin Chem Biol 2005;9:674-9.
32. Li JG, Li WX, Xu JY, Cai XQ, Liu RL, Li YJ, et al. Comparative study
of pathological lesions induced by multiwalled carbon nanotubes in
lungs of mice by intratracheal instillation and inhalation. Environ
Toxicol 2007;22:415-21.
33. Shi XF, Sitharaman B, Pham QP, Liang F, Wu K, Billups WE, et al.
Fabrication of porous ultra-short single-walled carbon nanotube
nanocomposite scaffolds for bone tissue engineering. Biomaterials
2007;28:4078-90.
34. Ali-Boucetta H, Al-Jamal KT, McCarthy D, Prato M, Bianco A,
Kostarelos K. Multiwalled carbon nanotube-doxorubicin supramolecular
complexes for cancer therapeutics. Chem Commun 2008:459-61.
35. Heister E, Neves V, Tîlmaciu C, Lipert K, Beltrán VS, Coley HM, et al.
Triple functionalisation of single-walled carbon nanotubes with
doxorubicin, a monoclonal antibody, and a fluorescent marker for
targeted cancer therapy. Carbon 2009;47:2152-60.
36. Pantarotto D, Partidos CD, Hoebeke J, Brown F, Kramer E, Briand J-P, et al.
Immunization with peptide-functionalized carbon nanotubes enhances virus-
specific neutralizing antibody responses. Chem Biol 2003;10:961-6.
37. Pondman KM, Maijenburg AW, Celikkol FB, Pathan AA, Kishore U,
ten Haken B, et al. Au coated Ni nanowires with tuneable dimensions for
biomedical applications. J Mater Chem B 2013;1:6129-36.
38. Kishore U, Ghai R, Greenhough TJ, Shrive AK, Bonifati DM, GadjevaMG,
et al. Structural and functional anatomy of the globular domain of
complement protein C1q. Immunol Lett 2004;95:113-28.
39. Sim RB, Reid KB. C1: molecular interactions with activating systems.
Immunol Today 1991;12:307-11.
40. Kishore U, Gupta SK, Perdikoulis MV, Kojouharova MS, Urban BC, Reid
KBM. Modular organization of the carboxyl-terminal, globular head region
of human C1q A, B, and C chains. J Immunol 2003;171:812-20.
41. Gaboriaud C, Juanhuix J, Gruez A, Lacroix M, Darnault C, Pignol D, et al.
The crystal structure of the globular head of complement protein C1q
provides a basis for its versatile recognition properties. J Biol Chem
2003;278:46974-82.42. Ghai R, Waters P, Roumenina LT, Gadjeva M, Kojouharova MS,
Reid KBM, et al. C1q and its growing family. Immunobiology
2007;212:253-66.
43. Balavoine F, Schultz P, Richard C, Mallouh V, Ebbesen TW,
Mioskowski C. Helical crystallization of proteins on carbon nanotubes:
a first step towards the development of new biosensors. Angew Chem Int
Ed Engl 1999;38:1912-5.
44. Pan B, Xing B. Adsorption mechanisms of organic chemicals on carbon
nanotubes. Environ Sci Technol 2008;42:9005-13.
45. Pulskamp K, Diabaté S, Krug HF. Carbon nanotubes show no sign of
acute toxicity but induce intracellular reactive oxygen species in
dependence on contaminants. Toxicol Lett 2007;168:58-74.
46. Ji Z, Zhang D, Li L, Shen X, Deng X, Dong L, et al. The hepatotoxicity
of multi-walled carbon nanotubes in mice. Nanotechnology
2009;20:445101.
47. Boncel S, Muller KH, Skepper JN, Walczak KZ, Koziol KK. Tunable
chemistry and morphology of multi-wall carbon nanotubes as a route to
non-toxic, theranostic systems. Biomaterials 2011;32:7677-86.
48. Jain S, Thakare VS, Das M, Godugu C, Jain AK, Mathur R, et al.
Toxicity of multiwalled carbon nanotubes with end defects critically
depends on their functionalization density. Chem Res Toxicol
2011;24:2028-39.
49. Zhao Y, Allen BL, Star A. Enzymatic degradation of multiwalled carbon
nanotubes. J Phys Chem A 2011;115:9536-44.
50. Muller J, Huaux F, Fonseca A, Nagy JB, Moreau N, Delos M, et al.
Structural defects play a major role in the acute lung toxicity of
multiwall carbon nanotubes: toxicological aspects. Chem Res Toxicol
2008;21:1698-705.
51. Singh RP, Das M, Thakare V, Jain S. Functionalization density
dependent toxicity of oxidized multiwalled carbon nanotubes in a
murine macrophage cell line. Chem Res Toxicol 2012;25:2127-37.
52. Wick P, Manser P, Limbach LK, Dettlaff-Weglikowska U, Krumeich F,
Roth S, et al. The degree and kind of agglomeration affect carbon
nanotube cytotoxicity. Toxicol Lett 2007;168:121-31.
53. Heister E, Lamprecht C, Neves V, Tîlmaciu C. Higher dispersion
efficacy of functionalized carbon nanotubes in chemical and biological
environments. ACS Nano 2010;4:2615-26.
54. Liu X, Hurt RH, Kane AB. Biodurability of single-walled
carbon nanotubes depends on surface functionalization. Carbon
2010;48:1961-9.
55. Kagan VE, Konduru NV, Feng W, Allen BL, Conroy J, Volkov Y, et al.
Carbon nanotubes degraded by neutrophil myeloperoxidase induce less
pulmonary inflammation. Nat Nanotechnol 2010;5:354-9.
56. Russier J, Ménard-Moyon C, Venturelli E, Gravel E, Marcolongo G,
Meneghetti M, et al. Oxidative biodegradation of single- and multi-
walled carbon nanotubes. Nanoscale 2011;3:893-6.
57. McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR,
Antczak C, et al. Tumor targeting with antibody-functionalized,
radiolabeled carbon nanotubes. J Nucl Med 2007;48:1180-9.
58. Xiao Y, Gao X, Taratula O, Treado S, Urbas A, Holbrook RD, et al.
Anti-HER2 IgY antibody-functionalized single-walled carbon nanotubes
for detection and selective destruction of breast cancer cells. BMC
Cancer 2009;9:351.
59. Cardoso MM, Peca IN, Roque ACA. Antibody-conjugated nanoparticles
for therapeutic applications. Curr Med Chem 2012;19:3103-27.
60. Lee IH, Lee JM, Jung Y. Controlled protein embedment onto Au/Ag
core-shell nanoparticles for immuno-labeling of nanosilver surface. ACS
Appl Mater Interfaces 2014;6:7659-64.
